Investigational drug · Phase 2
BIIB091
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsing Forms of Multiple Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "BIIB091"
First trial start
2023
Jul 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BIIB091", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing Forms of Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BIIB091" as an intervention, largest first.
- A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT05798520 · 127 participants · Start Jul 25, 2023 · Primary completion Feb 10, 2026
Drug: BIIB091; DRF and 1 more · For: Relapsing Forms of Multiple Sclerosis
Sites: Scottsdale, Arizona; Berkeley, California; Orange, California · 77 sites in all
BiogenBiogen (BIIB)
NCT06574828 · 69 participants · Start Aug 29, 2024 · Primary completion Mar 22, 2025
Drug: BIIB091; Moxifloxacin and 2 more · For: Healthy Volunteer
Sites: Austin, Texas
BiogenBiogen (BIIB)
NCT03943056 · 64 participants · Start May 13, 2019 · Primary completion Jan 10, 2020
Drug: BIIB091; Placebo · For: Healthy Volunteer
Sites: Dallas, Texas
BiogenBiogen (BIIB)
NCT04564612 · 59 participants · Start Sep 28, 2020 · Primary completion Sep 7, 2022
Drug: BIIB091; Rabeprazole and 1 more · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
BiogenBiogen (BIIB)
NCT06640933 · 25 participants · Start Oct 16, 2024 · Primary completion Feb 7, 2025
Drug: BIIB091 · For: Healthy Volunteer
Sites: Las Vegas, Nevada; Austin, Texas
BiogenBiogen (BIIB)
NCT06311786 · 8 participants · Start Apr 8, 2024 · Primary completion May 11, 2024
Drug: [14C]-BIIB091 · For: Healthy Volunteer
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants.
Tsai HH, Gu Y, Riester K, et al. · Drug Des Devel Ther 2026
- Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Geladaris A, Torke S, Weber MS · CNS Drugs 2022
- Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
Hopkins BT, Bame E, Bajrami B, et al. · J Med Chem 2022
- Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Bame E, Tang H, Burns JC, et al. · Clin Transl Immunology 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.